Durvalumab (anti-PD-L1) is approved as a maintenance therapy in patients with unresectable stage III NSCLC whose disease has not progressed following concurrent platinum-based chemoradiotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.